Atopic dermatitis (eczema) is a long-term inflammatory skin condition that causes itching, redness, and flare-ups that can make daily life difficult. It often begins in childhood but can occur at any age. Many people continue to experience uncontrolled symptoms and side effects from current treatments, even with available medicines.
This study is evaluating a new investigational medicine that may help treat atopic dermatitis symptoms in adults with moderate to severe atopic dermatitis
The investigational medicine works by targeting a specific immune pathway that helps the body’s own cells control inflammation. By supporting this natural immune balance, the medicine may help reduce flare-ups, calm inflammation, and support skin healing without broadly suppressing the immune system.
The study will test how safe and well-tolerated the investigational medicine is and whether it can treat skin health and overall symptoms in people living with atopic dermatitis.
You may be eligible if:
If eligible, you will take part in the study for about 12 months, including screening, treatment, and follow-up.
The study involves 17 clinic visits, including 5 fasting visits, and regular health and skin assessments throughout the treatment and follow-up periods.
Participants will receive subcutaneous (under the skin) injections of either the investigational medicine or a placebo once every four weeks for 12 weeks. During the study, doctors will monitor your skin symptoms, safety, and overall health through regular check-ups, blood tests, and skin assessments to understand how the investigational medicine works.
During the study, participants will undergo comprehensive health and skin assessments, including:
These assessments will help the study team monitor safety, treatment response, and changes in skin health over time.
Eligible participants will receive reimbursement for study-related time and travel.